Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of nine systematic review(s)/meta-analysis(es). ^[1-9]
• Bimekizumab was highly effective in achieving Psoriasis Area and Severity Index (PASI) 75, 90, and 100 in patients with moderate-to-severe psoriasis, with relative risks (RR) of 20.54 for PASI 75, 16.99 for PASI 90, and 14.57 for PASI 100 compared to placebo.
• Network meta-analyses indicated that bimekizumab had a high probability of achieving PASI 75 (92.3%), PASI 90 (84.0%), and PASI 100 (57.8%) within 10-16 weeks, demonstrating superior effectiveness compared to secukinumab, brodalumab, and guselkumab.
• Bimekizumab's effectiveness was comparable to other leading biologics, such as ixekizumab and risankizumab, with consistently higher efficacy in PASI 90 and PASI 100 thresholds compared to several other treatments.
• There was no significant difference in the risk of serious adverse events (SAES) between bimekizumab and placebo (RR: 0.67), with low to moderate certainty in evidence across multiple network meta-analyses.
• No significant difference in treatment-emergent adverse events (TEAES) was observed between bimekizumab and placebo (RR: 1.17), suggesting a similar safety profile to other anti-IL17 drugs, including ixekizumab and secukinumab.
• No significant differential treatment outcomes were reported for skin of color (SOC) participants across treatment groups, including bimekizumab, adalimumab, ixekizumab, secukinumab, and ustekinumab, although baseline characteristics and comorbidities varied, suggesting the need to consider ethnic background in treatment decisions.